Send to

Choose Destination
Cancer Treat Rep. 1980;64(12):1247-51.

Phase I study of 6-diazo-5-oxo-L-norleucine (DON).


We conducted a phase I study of 6-diazo-5-oxo-L-norleucine given iv on a twice weekly schedule. Twenty-six evaluable patients received 31 courses of the drug. Doses ranged from 100 to 500 mg/m2. Nausea with vomiting was the dose-limiting toxic effect, transient thrombocytopenia was seen frequently, and mucositis occurred in 39% of the patients. No definite therapeutic responses were observed in 18 patients with measurable lesions. The recommended dose for phase II studies is 200-300 mg/m2 iv twice weekly.

[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center